Merck gets FDA nod for allergy drug

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

An FDA advisory committee panel unanimously agrees the available data support the efficacy and safety of Merck's (MRK) GRASTEK for treating pollen allergy in those aged 5 and up. The panel did recommend post-approval studies for those aged 5-11, citing some side effects.